MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.

This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad’s Precise MRD.

“We look forward to working with MD Anderson to evaluate Precise MRD’s utility in cancer care,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “Our collaborative studies will explore how our ultrasensitive Precise MRD test can enhance treatment strategies for providers and improve patient outcomes. We are optimistic that our MRD test’s ability to quantitatively detect tumor-derived DNA at very low levels — far lower than is possible with first-generation MRD tests — will open new opportunities for therapy-response and recurrence monitoring.”

Under the terms of the agreement, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test’s utility in breast, gastrointestinal, genitourinary, and gynecological cancers. The goal of these studies is to generate evidence that supports national guideline inclusion and healthcare provider adoption. MD Anderson investigators will lead patient enrollment, sample collection, clinical data analysis and manuscript writing. Myriad will provide funding, MRD testing and scientific research support as well as potential milestone and royalty payments under the collaboration.

“This strategic alliance brings together cutting-edge technology and expertise from Myriad with disease-focused expertise and clinical trials excellence from MD Anderson,” said , division head of Cancer Medicine at MD Anderson. “We aim to explore numerous applications for MRD testing, including monitoring patients for relapse after treatment, identifying high-risk patients in need of clinical trials, and potentially intervention approaches.”

The alliance expands upon existing collaborations between MD Anderson researchers and Myriad, including ongoing studies in breast cancer and renal cell carcinoma.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .

About MD Anderson

in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that Myriad will work with MD Anderson to evaluate Precise MRD’s utility in cancer care, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test’s utility in breast, gastrointestinal, genitourinary, and gynecological cancers, the collaborative studies will explore how the Precise MRD test can enhance treatment strategies for providers and improve patient outcomes, and Myriad’s belief that its MRD test’s ability to quantitatively detect tumor-derived DNA at very low levels will open new opportunities for therapy-response and recurrence monitoring. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact 

Matt Scalo 

(801) 584-3532 

 

Media Contact 

Glenn Farrell 

(385) 318-3718